Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.52 |
| ▸ | RAB9A | P51151 | 7/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 6/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.50 |
| ▸ | RARA | P10276 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4114732 | 0.88 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1MAPTKDM4ETP53 | |
| SCHEMBL14527733 | 0.87 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1RAB9ALMNAMAPT | |
| SCHEMBL1425593 | 0.86 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL1426050 | 0.86 | MAPT (0.52) | ALDH1A1L3MBTL1SMN1; SMN2RAB9ALMNA | |
| SCHEMBL18614346 | 0.86 | MAPT (0.54) | ALDH1A1L3MBTL1SMN1; SMN2RAB9ALMNA | |
| SCHEMBL1425605 | 0.85 | MAPT (0.61) | ALDH1A1L3MBTL1SMN1; SMN2RAB9ALMNA | |
| SCHEMBL21348642 | 0.84 | TDP1 (0.53) | ALDH1A1L3MBTL1SMN1; SMN2RAB9ALMNA | |
| SCHEMBL4164682 | 0.84 | FOS (0.46) | ALDH1A1L3MBTL1RAB9ALMNAMAPT | |
| SCHEMBL4101439 | 0.83 | PPARD (0.44) | ALDH1A1L3MBTL1SMN1; SMN2RAB9ALMNA | |
| SCHEMBL4114734 | 0.82 | MAPT (0.55) | ALDH1A1L3MBTL1MAPTKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12433895-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20240335448-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | PHARMARESROUCES (SHANGHAI) CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| US-11844758-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-12-19 | — | — | US | disclosed |
| CN-111087353-B | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| US-20220354856-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2022-11-10 | — | — | US | disclosed |
| US-10946023-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10946023-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3686190-A1 | SYNTHESIS OF THERAPEUTICALLY ACTIVE COMPOUNDS | Agios Pharmaceuticals, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| CN-111087353-A | Therapeutically active compounds and methods of use thereof | 安吉奥斯医药品有限公司 | 2020-05-01 | — | — | CN | disclosed |
| CN-105473560-B | Therapeutically active compounds and methods of use thereof | 安吉奥斯医药品有限公司 | 2020-01-17 | — | — | CN | disclosed |
| US-20170107194-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-04-20 | — | — | US | disclosed |
| US-20170107194-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-04-20 | — | — | US | disclosed |
| US-9579324-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9579324-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9579324-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160220572-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160220572-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160220572-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-08-04 | — | — | US | disclosed |
| EP-3019483-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015003640-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433895-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | ALDH1A1 923/4885L3MBTL1 1106/4885SMN1; SMN2 568/4885 |
| US-11844758-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | ALDH1A1 923/4885L3MBTL1 1106/4885SMN1; SMN2 568/4885 |
| US-20240335448-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | ALDH1A1 923/4885L3MBTL1 1106/4885SMN1; SMN2 568/4885 |
| US-10946023-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | ALDH1A1 923/4885L3MBTL1 1106/4885SMN1; SMN2 568/4885 |
| US-20160220572-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | ALDH1A1 923/4885L3MBTL1 1106/4885SMN1; SMN2 568/4885 |
| US-20170107194-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | ALDH1A1 923/4885L3MBTL1 1106/4885SMN1; SMN2 568/4885 |
| US-20220354856-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | ALDH1A1 923/4885L3MBTL1 1106/4885SMN1; SMN2 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.